2022 Result of ANNUAL GENERAL MEETING – all resolutions passed

28th June 2022 - 12:42 pm

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below.

ImmuPharma’s Chairman & CEO, Tim McCarthy said: “We are delighted to have had such overwhelming support from right across our shareholder base. This includes corporate, institutional and long-term private shareholders, in respect to all of the AGM resolutions. The support for the re-appointment of the new Board, an integral part of the management restructuring, successfully completed in August last year, being part of the resolutions being approved.

 Importantly, we also announced yesterday, a key progress update on our lead programme, Lupuzor™. Our partner, Avion Pharmaceuticals, who is also a major supportive shareholder, has confirmed that having met all the Food and Drug Administration’s (“FDA”) requirements, they have sought final guidance from the FDA, as they actively prepare for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients. This is a key inflection point for the positive progress of Lupuzor™ towards becoming a first line therapy to many Lupus sufferers globally.

 On behalf of the new Board, I would like to thank all our shareholders and collaborators for their continued belief in ImmuPharma.”

Resolution For % For Against % Against Withheld
1. To receive the accounts of the Company for the year ended 31 December 2021 together with the reports thereon of the directors and auditors of the Company 53,394,853

 

99.14

 

463,666

 

0.86

 

837,178

 

2. To re-appoint Tim McCarthy as a director of the Company 53,310,582

 

98.99

 

542,318

 

1.01

 

842,797

 

3. To re-appoint Dr Tim Franklin as a director of the Company 53,300,349

 

99.00

 

540,213

 

1.00

 

855,135

 

4. To re-appoint Dr Sanjeev Pandya as a director of the Company 53,304,688

 

99.00

 

535,874

 

1.00

 

855,135

 

5. To re-appoint Lisa Baderoon as a director of the Company 53,304,363

 

99.00

 

536,199

 

1.00

 

855,135

 

6. To re-appoint Nexia Smith & Williams as auditors of the Company 53,280,466

 

99.02

 

527,057

 

0.98

 

888,174

 

7. That subject to the passing of resolution 10, each ordinary share of £0.10 in the capital of the Company be sub-divided into one ordinary share of £0.01 each and one deferred share of £0.09 each 53,000,307

 

98.47

 

821,831

 

1.53

 

873,559

 

8. That the Directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the “Act”) to allot shares on the basis as set out in the Notice of Meeting. Special Resolution 52,999,192

 

98.58

 

765,320

 

1.42

 

931,185

 

9. That, subject to the passing of Resolution 8, the Directors are hereby empowered pursuant to section 571 of the Act to allot equity securities on the basis as set out in the Notice of Meeting 52,972,066

 

98.53

 

792,446

 

1.47

 

931,185

 

10. That, subject to the passing of resolution 7, the articles of association of the Company be amended as set out in the Notice of Meeting 52,992,957

 

98.56

 

772,458

 

1.44

 

930,282

 

As at the date of the AGM, the number of issued ordinary shares of the Company was 284,984,933 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company’s Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote “for” or “against” a resolution. Proxy appointments which gave discretion to the Chairman have been included in the “for” total.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Click here to download announcement

Share this article